Update study of GLP-1 receptor agonist in the treatment of non-alcoholic fatty liver disease
10.11958/j.issn.0253-9896.2015.11.004
- VernacularTitle:GLP-1受体激动剂治疗非酒精性脂肪肝的新进展
- Author:
Chunjun LI
;
Demin YU
- Publication Type:Journal Article
- Keywords:
glucagon-like peptide 1;
incretins;
fatty liver;
review;
glucogon-like peptide 1 receptor agonist;
non-alco-holic fatty liver
- From:
Tianjin Medical Journal
2015;(11):1230-1234
- CountryChina
- Language:Chinese
-
Abstract:
Non-alcoholic fatty liver disease (NAFLD) is one of the most common diseases across the world, but there is still no specific treatment for NAFLD. Glucogon-like peptide 1 receptor agonist (GLP-1Ra) is a novel drug for the treatment of type 2 diabetes, based on incretin hormone target. Animal and clinical studies have demonstrated that GLP-1Ra can effec?tively reduce fat deposit in liver and attenuate hepatic steatosis. Therefore, GLP-1Ra is a promising therapeutic approachagainst NAFLD. In this review, we provided an overview of the clinical and basic research evidences and mechanisms in re?lieving NAFLD.
